Who Owns Gushengtang Holdings Company?

Gushengtang Holdings Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Gushengtang Holdings Company?

Gushengtang Holdings Limited, a key player in China's Traditional Chinese Medicine (TCM) sector, operates a network of medical institutions and online platforms. Founded in 2012 and incorporated in the Cayman Islands, the company went public on the Hong Kong Stock Exchange in December 2021.

The company's ownership structure is a blend of its founders, institutional investors, and the public. This mix influences its strategic decisions and market approach.

Understanding Gushengtang's ownership is key to grasping its market dynamics and future growth, especially in the expanding TCM industry. For a deeper dive into its operational environment, consider the Gushengtang Holdings PESTEL Analysis.

Gushengtang Holdings Limited was established in 2012, with its official incorporation in the Cayman Islands occurring on May 8, 2014. Mr. Tu Zhiliang is recognized as the principal founder and a dominant force from the company's inception, serving as Chairman and Chief Executive Officer since August 21, 2014.

Founding Vision

Mr. Tu Zhiliang envisioned integrating modern technology with traditional Chinese medicine. The focus was on developing and distributing herbal medicines and related products.

Early Ownership Control

Early ownership structures indicate Mr. Tu Zhiliang's significant control. This was established through direct and indirect shareholdings and voting deeds.

Founder's Stake

As of March 30, 2023, Mr. Tu Zhiliang was interested in 30,043,777 directly held shares. He also controlled voting rights for an additional 24,415,105 shares.

Wholly Owned Entities

Directly held shares were through entities like the Vendor and Celestial City. Both are wholly owned by Wumianshan Ltd., which is entirely owned by Mr. Tu.

Voting Rights

Voting rights for 24,415,105 shares are held via voting deeds. These shares are held by various entities including Gushengtang Ltd. and Shiyimianshan Holdings Limited.

Founder-Led Control

The existing ownership structure highlights a strong founder-led control. This has been a consistent element throughout the company's growth and development.

The initial equity distribution among all founders at the company's inception is not extensively detailed in public records. However, the current ownership framework clearly demonstrates Mr. Tu Zhiliang's substantial influence and control over the company's strategic direction from its early stages. This founder-centric approach has been a key element in the company's Growth Strategy of Gushengtang Holdings.

Key Ownership Details

Mr. Tu Zhiliang is the primary founder and holds significant control over Gushengtang Holdings. His leadership has guided the company's integration of technology with traditional Chinese medicine.

• Mr. Tu Zhiliang is the Chairman and CEO.
• The company was incorporated in the Cayman Islands on May 8, 2014.
• As of March 30, 2023, Mr. Tu controlled over 54 million shares through direct and indirect holdings and voting deeds.
• Early ownership reflected a strong founder-led control.
• The company's vision centers on herbal medicine development and distribution.

Gushengtang Holdings SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Gushengtang Holdings Limited's ownership structure underwent a significant transformation following its initial public offering on the Hong Kong Stock Exchange (HKEX) on December 10, 2021. This event, which raised approximately HK$808 million (US$104 million), marked the beginning of a more diversified ownership landscape, moving beyond its initial founder-controlled base.

The current ownership of Gushengtang Holdings Limited reflects a blend of founder influence, private company holdings, and a substantial allocation to institutional and public investors. As of mid-2025, institutional investors collectively hold approximately 32.8% of the company's shares, indicating a growing reliance on external capital and a broadening base of stakeholders. This shift in ownership dynamics, particularly the increase in institutional backing, is instrumental in fueling the company's strategic expansion initiatives, such as the acquisitions of Hunan Mingyuantang in May 2024 for RMB18 million and Hangzhou Yong Chun Tang in September 2024. These developments not only provide capital for growth but also introduce diverse perspectives into the company's governance, balancing the founder's vision with broader market expectations and contributing to a more robust corporate structure.

Key Ownership Insights

Understanding Gushengtang Holdings ownership is crucial for assessing its strategic direction and stability. The increasing institutional stake suggests a growing confidence from the financial markets.

• Founder, Tu Zhiliang, maintains a significant direct stake of 9.3%.
• Institutional investors represent a substantial portion of ownership at 32.8%.
• Private companies hold 17% of the shares, contributing to the company's structure.
• The general public owns 40.5%, reflecting broad market participation.
• Recent acquisitions highlight the impact of ownership on strategic growth.

Gushengtang Holdings PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of August 2025, Gushengtang Holdings Limited's Board of Directors is composed of executive, non-executive, and independent non-executive members. Mr. Tu Zhiliang holds the positions of Chairman and executive Director, also serving as the CEO and a significant shareholder, indicating his substantial influence over the company's direction.

The board structure includes key committees to oversee financial reporting and executive compensation. Mr. Li Tie chairs the Audit Committee, which also includes Mr. Huang Jingsheng and Mr. Zhong Weihe. Ms. Wang Lan leads the Remuneration Committee, with Mr. Li Tie also serving as a member. The management team and the board of directors both have an average tenure of approximately 4 years, suggesting a seasoned leadership group. The company's Mission, Vision & Core Values of Gushengtang Holdings likely guides the strategic decisions made by this experienced board.

Gushengtang Holdings Voting Power Dynamics

Mr. Tu Zhiliang, the Chairman, wields considerable voting power within Gushengtang Holdings. This control extends beyond his direct equity stake of 9.3%, encompassing voting rights from various wholly-owned entities and other holding companies.

• Mr. Tu Zhiliang is the primary controlling shareholder.
• Significant voting power is consolidated through multiple corporate entities.
• This structure reflects a founder-centric governance model.
• No recent activist investor campaigns or proxy battles have been reported.

Gushengtang Holdings Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past 3-5 years, Gushengtang Holdings Limited has experienced significant strategic maneuvers, including acquisitions and share repurchases, indicating a dynamic approach to growth and capital management. These activities have aimed to bolster its market presence and shareholder value, with recent financial forecasts showing robust performance.

Gushengtang Holdings has demonstrated a commitment to expanding its physical footprint and integrating advanced technology into its operations. The company's strategic acquisitions in May and September 2024, acquiring full ownership of Hunan Mingyuantang Traditional Chinese Medicine Development Co., Ltd. and Hangzhou Yong Chun Tang TCM Out-patient Department Co., Ltd. respectively, underscore its objective to broaden its network of offline medical institutions. Concurrently, the cancellation of approximately 0.4 million shares on July 17, 2025, reflects a strategy to manage share capital without significant dilution for existing shareholders. The company's financial outlook for the first half of 2025 is positive, with projected revenue increases of 8% to 12% and net profit growth of 39% to 44%. This growth is supported by industry trends favoring technology integration in Traditional Chinese Medicine (TCM), as evidenced by the August 2025 launch of the Gu Shengtang National Medicine AI System. Analyst expectations point to continued strong performance, with forecasts of 22.5% annual earnings growth and 20.1% annual revenue growth, driven by policy support and increasing consumer health awareness. The upcoming board meeting on August 29, 2025, will further solidify these financial plans and potential dividend distributions, offering insights into Revenue Streams & Business Model of Gushengtang Holdings.

Strategic Expansion Through Acquisitions

Gushengtang Holdings acquired 100% of Hunan Mingyuantang TCM Development for RMB18 million in May 2024 and Hangzhou Yong Chun Tang TCM Out-patient Department in September 2024.

Capital Management and Shareholder Value

The company canceled approximately 0.4 million shares on July 17, 2025, aiming to maintain shareholder value without significant dilution.

Financial Performance and Outlook

First-half 2025 revenue is projected between RMB1,474 million and RMB1,529 million, with net profit expected to increase by 39% to 44%.

Technological Integration in TCM

The launch of the Gu Shengtang National Medicine AI System in August 2025 highlights the company's focus on leveraging AI for improved TCM services.

Gushengtang Holdings Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔